Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:32 PM ET Form 4
Insider Selling Steris plc STE

Steris Sr. Vice Pres., CFO Karen L. Burton Sells $1.5M of Stock

Karen L. Burton, Sr. Vice Pres., CFO, sold 5,880 shares of Steris plc at $255.62 a share, worth $1.5M in total on Nov 11, 2026. Shares held after the trade: 12,956 (-31.2%).

Value
$1.5M
Shares
5,880
Price
$255.62
Role
Sr. Vice Pres., CFO
Holding change
-31.2%
Trade date
Nov 11, 2026
4:32 PM ET Form 4
Insider Selling Steris plc STE

Steris Insider Mohsen Sohi Sells $1.24M of Stock

Mohsen Sohi sold 4,893 shares of Steris plc at $252.87 to $253.90 a share (average $253.22) in 2 transactions, worth $1.24M in total on Nov 10, 2026. Shares held after the trade: 24,305 (-6.4%).

Value
$1.24M
Shares
4,893
Average price
$253.22
Holding change
-6.4%
Trade date
Nov 10, 2026
4:32 PM ET 10-Q
Financial Results GEN Restaurant Group, Inc. GENK

GEN Restaurant Group Q3 2026 Results: Net Loss of $1.03M, Loss Widens

GEN Restaurant Group reported a net loss of $17.3 million for the nine months ended September 30, 2026, compared to a $7.3 million loss in the prior year period, as restaurant operating expenses rose despite a slight decline in revenue. The company's total assets decreased to $247.2 million from $259.9 million at year-end 2025, while its cash position remained relatively stable at $2.9 million.

Key figure
Net loss $1.03M
4:32 PM ET 8-K
Financial Results Virgin Galactic Holdings, Inc SPCE

Virgin Galactic Holdings Financial Results

Virgin Galactic reported Q3 2026 financial results, including revenue of $0.4 million and a net loss of $59 million. The company announced plans for a $250 million at-the-market equity offering and potential debt-for-equity exchanges to fund operations and capacity expansion ahead of commercial flights expected in 2027.

Term
Q3 2026

“Spaceship Apeiron’s arrival at Spaceport America shifts our focus towards operational readiness, as we now prepare for flight test and the launch of commercial spaceflight. With our second spaceship on track to join Apeiron and Eve in late Q2/early Q3 2027, we have initiated near-term growth projects expected to increase capacity from this initial fleet to a rate of 150 spaceflights per year by the end of 2028.”

Michael Colglazier, Chief Executive Officer of Virgin Galactic
4:32 PM ET 10-Q
Financial Results Lulu's Fashion Lounge Holdings, Inc. LVLU

Lulu's Fashion Lounge Holdings Q3 2026 Results: Net Loss of $4.26M, Loss Widens

Lulu's Fashion Lounge Holdings, Inc. reported a significant decline in net revenue for the thirteen weeks ended September 27, 2026, falling to $58.6 million from $73.6 million in the prior year period. The company's stockholders' equity turned to a deficit of $5.0 million as of September 27, 2026, driven by an accumulated deficit of $272.0 million.

Key figure
Net loss $4.26M
4:32 PM ET 10-Q
Financial Results Quantum Cyber N.V. QUCY

Quantum Cyber Q3 2026 Results: Net Loss of $5.38M, Loss Widens

Quantum Cyber N.V. reported a significant increase in revenue to $0.97 million for the nine months ended September 30, 2026, compared to zero in the prior year, though net loss widened to $21.5 million. The company strengthened its balance sheet through $22.2 million in financing activities, primarily from warrant exercises and preferred share issuances, resulting in a total cash position of $4.89 million.

Key figure
Net loss $5.38M
4:32 PM ET 10-Q
Financial Results Sunshine Biopharma Inc. SBFM

Sunshine Biopharma Q3 2026 Results: Net Loss of $1.22M, Loss Widens

Sunshine Biopharma Inc. reported a net loss of $4.03 million for the nine months ended September 30, 2026, compared to a loss of $3.83 million in the prior year period. While revenues decreased slightly to $26.79 million, the company significantly strengthened its cash position to $14.62 million through public offerings and warrant exercises.

Key figure
Net loss $1.22M
4:32 PM ET 10-Q
Financial Results Aethlon Medical Inc AEMD

Aethlon Medical Q2 2026 Results: Net Loss of $2.62M, Loss Widens

Aethlon Medical reported a net loss of $4.17 million for the six months ended September 30, 2026, compared to $3.25 million in the prior year period, driven largely by increased professional fees. The company is currently pursuing a merger with North Immunology, Inc. and has raised capital through common stock issuances to maintain a cash balance of approximately $6.49 million.

Key figure
Net loss $2.62M
4:32 PM ET 10-Q
Financial Results Willamette Valley Vineyards Inc WVVI

Willamette Valley Vineyards Q3 2026 Results: Net Loss of $1.05M, Loss Narrows

Willamette Valley Vineyards reported a net loss of $3.0 million for the nine months ended September 30, 2026, compared to a $1.7 million loss in the prior year period. Despite a 4.2% increase in net sales to $27.2 million, rising operating expenses and higher cost of sales contributed to a loss applicable to common shareholders of $0.97 per share.

Key figure
Net loss $1.05M
4:32 PM ET 10-Q
Financial Results BioStem Technologies, Inc. BSEM ▶ Call

BioStem Technologies Q3 2026 Results: Net Loss of $11.4M

BioStem Technologies reported a significant decline in revenue to $21.7 million for the nine months ended September 30, 2026, compared to $37.4 million in the prior year, resulting in a net loss from operations of $27.1 million. The company is facing liquidity challenges, including an unpaid $10 million clearance payment due to BioTissue and a substantial decrease in cash from $29.5 million to $971,145 over the nine-month period.

Key figure
Net loss $11.4M
4:32 PM ET 8-K
Other 8-K Filing Olema Pharmaceuticals, Inc. OLMA

Olema Oncology Other 8-K Filing

Olema Pharmaceuticals, Inc. has changed its corporate name to Olema Oncology, Inc. and relocated its principal executive offices to South San Francisco. The company's common stock will continue to trade on the Nasdaq Global Select Market under the existing ticker symbol OLMA.

4:32 PM ET 10-Q
Financial Results Eledon Pharmaceuticals, Inc. ELDN

Eledon Pharmaceuticals Q3 2026 Results: Net Loss of $3.93M, Loss Narrows

For the nine months ended September 30, 2026, Eledon Pharmaceuticals reported a net loss of $74.6 million, a significant increase from the $35.2 million loss in the prior year period, primarily driven by a $11.6 million unfavorable change in the fair value of warrant liabilities. Total assets decreased to $106.6 million from $169.0 million at year-end 2025, reflecting a reduction in cash and short-term investments used to fund ongoing research and development operations.

Key figure
Net loss $3.93M
4:32 PM ET 10-Q
Financial Results American Battery Technology Co ABAT

American Battery Technology Q1 2026 Results: Net Loss of $14.6M, Loss Widens

American Battery Technology Company reported a net loss of $14.6 million for the quarter ended September 30, 2026, compared to a $10.3 million loss in the prior year. While revenue increased to $1.7 million, the company faced a gross loss of $3.6 million and significantly higher operating expenses driven by general, administrative, and R&D costs.

Key figure
Net loss $14.6M
4:32 PM ET 10-Q
Financial Results Ensysce Biosciences, Inc. ENSC

Ensysce Biosciences Q3 2026 Results: Net Loss of $82.1M, Loss Widens

Ensysce Biosciences reported a significant net loss of $88.2 million for the nine months ended September 30, 2026, primarily driven by a $79.9 million charge for acquired in-process research and development. Despite the loss, the company strengthened its liquidity position, ending the period with $29.7 million in cash following multiple preferred stock and PIPE financing transactions.

Key figure
Net loss $82.1M
4:32 PM ET Form 4
Insider Selling Magnite, Inc. MGNI

Magnite Insider James Rossman Sells $1.43M of Stock

James Rossman sold 49,190 shares of Magnite, Inc. at $29.05 a share, worth $1.43M in total on Nov 11, 2026. Shares held after the trade: 58,287 (-45.8%).

Value
$1.43M
Shares
49,190
Price
$29.05
Holding change
-45.8%
Trade date
Nov 11, 2026
4:32 PM ET Form 4
Insider Selling Addus HomeCare Corp ADUS

Addus HomeCare EVP, Chief Govt Rel Officer Darby Anderson Sells $827K of Stock

Darby Anderson, EVP, Chief Govt Rel Officer, sold 6,740 shares of Addus HomeCare Corp at $122.30 to $123.41 a share (average $122.72) in 2 transactions, worth $827K in total on Nov 10, 2026. Shares held after the trade: 46,246 (-5.2%).

Value
$827K
Shares
6,740
Average price
$122.72
Role
EVP, Chief Govt Rel Officer
Holding change
-5.2%
Trade date
Nov 10, 2026
4:32 PM ET 10-Q
Financial Results Medicinova Inc MNOV

Medicinova Q3 2026 Results: Net Loss of $2.84M, Loss Narrows

MediciNova reported a net loss of $7.7 million for the nine months ended September 30, 2026, an improvement from the $9.2 million loss in the prior year period. The company strengthened its liquidity by raising $6.2 million through an at-the-market equity offering, ending the quarter with $29.3 million in cash and cash equivalents.

Key figure
Net loss $2.84M
4:32 PM ET Form 4
Insider Buying Claritev Corp CTEV

Claritev Insider Ares Management LLC Buys $2.94M of Stock

Ares Management LLC bought 115,579 shares of Claritev Corp at $24.42 to $26.14 a share (average $25.40) in 2 transactions, worth $2.94M in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 2,049,518 (+3.3%).

Value
$2.94M
Shares
115,579
Average price
$25.40
Holding change
+3.3%
Trade date
Nov 9, 2026 to Nov 10, 2026
4:31 PM ET 8-K
Financial Results Aethlon Medical Inc AEMD

Aethlon Medical Financial Results

Aethlon Medical reported financial results for its fiscal second quarter ended September 30, 2026, highlighting a cash position of $6.5 million and a 77.2% increase in operating expenses due to merger-related professional fees. The company is currently progressing through a definitive merger agreement with North Immunology, Inc., which includes a contingent value right (CVR) for existing shareholders related to the legacy Hemopurifier business.

“We advanced our clinical program during the quarter. We treated the second participant in the third and final dosing cohort of our Phase 1 oncology study in Australia. We have treated eight patients across the three dosing cohorts to date and continue to pursue enrollment of one additional patient.”

James Frakes, CEO and CFO
4:31 PM ET 8-K
M&A Deal Hagerty, Inc. HGTY

Hagerty Signs $148M M&A Deal with Hagerty Holding Corp.

Hagerty, Inc. announced the pricing and closing of a secondary offering of 10,000,000 shares of Class A common stock by its majority stockholder, Hagerty Holding Corp., at $14.85 per share. The company did not receive any proceeds from the sale, as the shares were previously issued and the offering was intended to facilitate a secondary sale by the selling stockholder.

Value
$148M
Counterparty
Hagerty Holding Corp.
4:31 PM ET 8-K
Stock Plan Amendment New Jersey Resources Corp NJR

New Jersey Resources Stock Plan Amendment

New Jersey Resources approved its Fiscal 2027 Officer Annual Incentive Plan and granted long-term incentive awards to its named executive officers. The awards include performance share units tied to total shareholder return and cumulative net financial earnings per share, as well as restricted stock units. The annual incentive plan sets target cash opportunities ranging from 40% to 110% of base salary based on financial and leadership performance criteria.

Term
Fiscal 2027
4:31 PM ET 8-K
Financial Results Prairie Operating Co. PROP

Prairie Operating Financial Results

Prairie Operating Co. reported its Q3 2026 financial results, highlighted by a 31% sequential revenue increase to $129.5 million and a 21% increase in sales volumes to 26,117 Boe/d. Despite the revenue growth, the company recorded a net loss of $34.0 million while generating $65.3 million in Adjusted EBITDA.

Term
Q3 2026

“Prairie’s third-quarter results demonstrate the strength of our assets and the excellent work our team continues to deliver across our development program. Average daily sales volumes increased 21% from the prior quarter to 2.4 MMboe or 26,117 Boe per day, driving revenue growth of 31% from the prior quarter to $129.5 million. We achieved that growth while reducing lease operating expense per Boe by 17% from the prior quarter, reflecting our continued focus on improving well performance and operating efficiency.”

Greg Patton, Chief Executive Officer

“Prairie generated $65.3 million of Adjusted EBITDA in the third quarter, an increase of 92% from the prior quarter, as sales volumes increased and unit operating costs declined. With Burnett and Castor now producing, our focus is on realizing the cash returns from the capital invested this year and carefully managing the spending required to sustain that production.”

Michael Shelly, Executive Vice President and Chief Financial Officer
4:31 PM ET 10-Q
Financial Results BlossomHill Therapeutics, Inc. BLSM

BlossomHill Therapeutics Q3 2026 Results: Net Loss of $24M, Loss Widens

BlossomHill Therapeutics is a clinical-stage biopharmaceutical company with two product candidates, BH-30643 and BH-30236, in early clinical development and one preclinical candidate, BH-501284. The company has incurred substantial losses since inception and anticipates continued losses as it advances its precision medicine programs for genetically defined cancers.

Key figure
Net loss $24M
4:31 PM ET Form 4
Insider Selling Addus HomeCare Corp ADUS

Addus HomeCare EVP, Chief Development Officer Cliff Donald Blessing Sells $429K of Stock

Cliff Donald Blessing, EVP, Chief Development Officer, sold 3,464 shares of Addus HomeCare Corp at $123.10 to $124.18 a share (average $123.90) in 2 transactions, worth $429K in total on Nov 10, 2026. Shares held after the trade: 6,719 (-27.7%).

Value
$429K
Shares
3,464
Average price
$123.90
Role
EVP, Chief Development Officer
Holding change
-27.7%
Trade date
Nov 10, 2026
4:31 PM ET Form 4
Insider Buying General American Investors Co Inc GAM

General American Investors Co VP Administration Eugene S. Stark Buys $21.9K of Stock

Eugene S. Stark, VP Administration, bought 1,000 shares of General American Investors Co Inc at $21.95 a share, worth $21.9K in total on Nov 12, 2026. Shares held after the trade: 40,000 (+2.6%).

Value
$21.9K
Shares
1,000
Price
$21.95
Role
VP Administration
Holding change
+2.6%
Trade date
Nov 12, 2026
4:31 PM ET 8-K
Financial Results Legacy Education Inc. LGCY

Legacy Education Financial Results

Legacy Education Inc. reported financial results for its fiscal first quarter ended September 30, 2026, featuring record student population growth of 5.4% year-over-year to 3,684 students. The company achieved revenue of $20.0 million and net income of $0.9 million while expanding its footprint with a new lease for its first planned campus outside California in Houston, Texas.

Term
Q1 2027
4:31 PM ET Form 4
Insider Selling Mgp Ingredients Inc CASK

Sempreon 10% Owner Caroline Lux Kaplan Sells $1.08M of Stock

Caroline Lux Kaplan, 10% Owner, sold 60,000 shares of Sempreon, Inc at $17.63 to $18.26 a share (average $17.94) in 2 transactions, worth $1.08M in total between Nov 10, 2026 and Nov 11, 2026. Shares held after the trade: 410,958 (-6.8%).

Value
$1.08M
Shares
60,000
Average price
$17.94
Role
10% Owner
Holding change
-6.8%
Trade date
Nov 10, 2026 to Nov 11, 2026
4:31 PM ET 8-K
Dividend National Bankshares Inc NKSH

National Bankshares Dividend

National Bankshares, Inc. declared a semi-annual cash dividend of $0.78 per share. The dividend is payable on December 1, 2026, to stockholders of record as of the close of business on November 23, 2026.

Term
semi-annual
4:31 PM ET 10-Q
Financial Results Legence Corp. LGN

Legence Q3 2026 Results: Turns Profitable, Net Income $89.6M

Legence Corp. reported significant growth in total assets to $3.83 billion as of September 30, 2026, up from $2.68 billion at year-end 2025, driven by increases in contract assets and intangible assets. The company maintained a dual-class share structure with 108,527,517 total shares outstanding and reported a reduction in its accumulated deficit from $309.9 million to $232.1 million during the period.

Key figure
Net income $89.6M
4:31 PM ET Form 4
Insider Buying Stevanato Group S.p.A. STVN

Stevanato Group S.p.A Director William J. Federici Buys $274K of Stock

William J. Federici, Director, bought 20,000 shares of Stevanato Group S.p.A. at $13.72 a share, worth $274K in total on Nov 9, 2026. Shares held after the trade: 46,991 (+74.1%).

Value
$274K
Shares
20,000
Price
$13.72
Role
Director
Holding change
+74.1%
Trade date
Nov 9, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.